Genmab Reports Phase 2 Data Showing Median Overall Survival Above Two Years
Genmab said updated Phase 2 results showed median overall survival of more than two years for petosemtamab plus pembrolizumab in first-line recurrent or metastatic head and neck squamous cell carcinoma.